Company: City of Hope
Liaison(s): Defu Zeng, Jyotirmoy Kusari, Arthur Riggs, Wei Zhou
COH has developed a novel bone marrow transplant (BMT) procedure that induces mixed chimerism without GvHD. This BMT procedure has demonstrated curative effects of autoimmune diseases in mice. The goal of the COH research team is to use this procedure to cure many autoimmune diseases and various hematological disorders in humans. The goal for the COH TMP group is to conduct market research and develop a potential business plan for COH to use upon successful human trials. To achieve this goal, the following deliverables were enacted: market analysis of target indications, key opinion leader (KOL) interviews for selected top indications, and construction of a financial model.